Japan’s Eisai Boosts Inventory For Possible Flu Pandemic
This article was originally published in PharmAsia News
Executive Summary
As a measure to ward off a possible flu pandemic, Eisai maintains three month's worth of drug inventories in three Japanese factories as well as factories in the U.S., Taiwan, China and Indonesia. Eisai also has secured two month's worth of inventories in drug materials, and has initiated a multiple-supplier system. Eisai sells products to over 70 countries and revenue from overseas markets accounts for 60 percent of its sales. President Haruo Naito said that even if stocking inventory costs more, it is necessary to ensure uninterrupted supply. Other companies such as Takeda are also considering taking similar inventory measures and Pfizer has made a manual according to different stages of a pandemic, and set up a system that is able to import drugs from China and the U.S. in a crisis. (Click here for more - Japanese language
You may also be interested in...
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.
CRN Has Standing For Steep Hill To Climb Challenging New York's Age-Restricted Sales
Federal judge finds “misreading of the legislation” in CRN’s argument that state “restricts access based purely on what has been said about the product or its ingredients.” But standing to challenge “means that only CRN is positioned right now to go before the court on behalf of industry,” says CEO Steve Mister.
Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217
The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.